Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial.
Cohen H, Hunt BJ, Efthymiou M, Arachchillage DR, Mackie IJ, Clawson S, Sylvestre Y, Machin SJ, Bertolaccini ML, Ruiz-Castellano M, Muirhead N, Doré CJ, Khamashta M, Isenberg DA, RAPS trial investigators. · 2016
Read Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial. by Cohen H, Hunt BJ, Efthymiou M, Arachchillage DR, Mackie IJ, Clawson S, Sylvestre Y, Machin SJ, Bertolaccini ML, Ruiz-Castellano M, Muirhead N, Doré CJ, Khamashta M, Isenberg DA, RAPS trial investigators. (2016) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5010562.txt.
Introduction
Hannah Cohen and the RAPS trial team report in The Lancet Haematology in 2016 on blood thinning for antiphospholipid syndrome. People with this condition form harmful clots and usually take warfarin, which needs steady dose checks. The trial asked whether a newer drug, rivaroxaban, could replace warfarin in patients who had already had a vein clot, some of whom also had lupus.
In two British hospitals, 116 patients were split at random to stay on warfarin or switch to a daily rivaroxaban dose. The main lab measure, a marker of clot-forming power at day 42, ran higher on rivaroxaban and did not meet the trial's set bar for equal standing. Still, no patient in either group had a new clot or major bleeding during the study. The authors judge the newer drug promising and handy, but call for more trials in higher-risk patients.
Catalog record
| CREATOR | Cohen H, Hunt BJ, Efthymiou M, Arachchillage DR, Mackie IJ, Clawson S, Sylvestre Y, Machin SJ, Bertolaccini ML, Ruiz-Castellano M, Muirhead N, Doré CJ, Khamashta M, Isenberg DA, RAPS trial investigators. |
|---|---|
| YEAR | 2016 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 49 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial By Hannah Cohen, Beverley J Hunt, Maria Efthymiou, Deepa R J Arachchillage, Ian J Mackie, Simon Clawson, Yvonne Sylvestre, Samuel J Machin, Maria L Bertolaccini, Maria Ruiz-Castellano, Nicola Muirhead, Caroline J Doré Published in: The Lancet. Haematology DOI: 10.1016/S2352-3026(16)30079-5 ABSTRACT Summary Background Rivaroxaban is established for the treatment and secondary prevention of venous thromboembolism, but whether it is useful in patients with antiphospholipid syndrome is uncertain. Methods This randomised, controlled, open-label, phase 2/3, non-inferiority trial, done in two UK hospitals, included patients with antiphospholipid syndrome who were taking warfarin for previous venous thromboembolism, with a target international normalised ratio of 2·5. Patients were randomly assigned 1:1 to continue with warfarin or receive 20 mg oral rivaroxaban daily. Randomisation was done centrally, stratified by centre and patient type (with vs without systemic lupus erythematosus). The primary outcome was percentage change in endogenous thrombin potential (ETP) from randomisation to day 42, with non-inferiority set at less than 20% difference from warfarin in mean percentage change. Analysis was by modified intention to treat. Other thrombin generation parameters, thrombosis, and bleeding were also assessed. Treatment effect was measured as the ratio of rivaroxaban to warfarin for thrombin generation. This trial is registered with the ISRCTN registry, number ISRCTN68222801. Findings Of 116 patients randomised between June 5, 2013, and Nov 11, 2014, 54 who received rivaroxaban and 56 who received warfarin were assessed. At day 42, ETP was higher in the rivaroxaban than in the warfarin group (geometric mean 1086 nmol/L per min, 95% CI 957–1233 vs 548, 484–621, treatment effect 2·0, 95% CI 1·7–2·4, p<0·0001). Peak thrombin generation was lower in the rivaroxaban group (56 nmol/L, 95% CI 47–66 vs 86 nmol/L, 72–102, treatment effect 0·6, 95% CI 0·5–0·8, p=0·0006). No thrombosis or major bleeding were seen. Serious adverse events occurred in four patients in each group. Interpretation ETP for rivaroxaban did not reach the non-inferiority threshold, but as there was no increase in thrombotic risk compared with standard-intensity warfarin, this drug could be an effective and safe alternative in patients with antiphospholipid syndrome and previous venous thromboembolism. Funding Arthritis Research UK, Comprehensive Clinical Trials Unit at UCL, LUPUS UK, Bayer, National Institute for Health Research Biomedical Research Centre. INTRODUCTION Thrombotic antiphospholipid syndrome is a potentially fatal and devastating disorder. The mainstay for secondary prevention of venous thromboembolism is anticoagulation with warfarin or other vitamin K antagonists.1, 2 Approximately 15% of patients with systemic lupus erythematosus have thrombotic antiphospholipid syndrome, which severely worsens the outlook.3 Antiphospholipid syndrome is classified as a rare disease,4 but a systematic review suggests that antiphospholipid antibodies are present in 10% of patients with deep vein thrombosis,5 which suggests possible underdiagnosis of antiphospholipid syndrome. Appropriate management of thrombotic antiphospholipid syndrome is crucial to minimise its harmful effects. Direct oral anticoagulants, including rivaroxaban,6 are licensed for the treatment and secondary prevention of venous thromboembolism and are established as therapeutic alternatives to low-molecular-weight heparins and vitamin K antagonists. Patients with antiphospholipid syndrome were probably included in phase 3 randomised controlled trials of direct oral anticoagulants, but, because antiphospholipid antibody status was not systematically documented in these trials, confirmation of the usefulness of direct oral anticoagulants in these patients is required. Generation of thrombin via the tissue factor pathway is integral to the blood coagulation process. Markers of in-vivo coagulation activation provide information about an individual's thrombogenic potential,7 and their concentrations should be reduced after anticoagulation.8 Thrombin generation triggered by tissue factor, therefore, seems to be a relevant marker.9 Thrombin generation acts as a global measure of anticoagulation and can show the anticoagulant effects of warfarin and rivaroxaban despite these drugs having different modes of action on the coagulation mechanism. The thrombin generation curve is quantified in terms of the lag time, time to peak thrombin generation, peak thrombin generation, and endogenous thrombin potential (ETP), which is the area under the curve. Warfarin reduces the ETP by 30–50% of that before warfarin or that in normal controls.10, 11 Rivaroxaban inhibits thrombin generation in whole blood and platelet-rich plasma,12 and the ETP may be used as a measure of anticoagulation intensity.13, 14 Research in contextEvidence before this studyWe searched MEDLINE and PubMed with the following phrases: “antiphospholipid syndrome”, “systemic lupus erythematosus”, “venous thromboembolism”, “new oral anticoagulants”, “novel oral anticoagulants”, “direct acting oral anticoagulants”, “direct inhibitors of coagulation”, “non-vitamin K antagonist oral anticoagulants”, “warfarin”, “coumadin”, “vitamin K antagonists”, “dabigatran”, “rivaroxaban”, “apixaban”, “edoxaban”, “thrombin generation”, and “in vivo coagulation activation markers”. Further information was also requested from the manufacturers of the individual direct oral anticoagulants. Thrombotic antiphospholipid syndrome is a potentially fatal and devastating disorder. Although the disorder is rare, antiphospholipid antibodies are thought to be present in 10% of patients with deep vein thrombosis, suggesting possible underdiagnosis of thrombotic antiphospholipid syndrome. Warfarin and other vitamin K antagonists are the standard of care for the secondary prevention of venous thromboembolism in patients with thrombotic antiphospholipid syndrome. These drugs, however, can be particularly problematic in patients with thrombotic antiphospholipid syndrome because of variable sensitivity of thromboplastins to lupus anticoagulant, which is present in many of these patients. Consequently, the international normalised ratio (INR), which is used to monitor warfarin treatment, might not accurately reflect anticoagulation intensity. Two randomised controlled trials in thrombotic antiphospholipid syndrome have reported no benefits with high-intensity versus standard-intensity warfarin in the prevention of recurrent thrombosis. Rivaroxaban and other direct oral anticoagulants are effective and safe compared with warfarin for the treatment and secondary prevention of venous thromboembolism. Although antiphospholipid antibody status was not systematically documented in randomised controlled trials of direct oral anticoagulants, it is likely that patients with antiphospholipid syndrome were included. In the Rivaroxaban in Antiphospholipid Syndrome (RAPS) non-inferiority trial, therefore, we aimed to confirm the usefulness of rivaroxaban in secondary prevention of venous thromboembolism in patients with antiphospholipid syndrome.Added value of this studyRAPS is slightly larger than the two previous randomised controlled trials in patient with thrombotic antiphospholipid syndrome, and our inclusion criteria enabled recruitment of a more homogeneous study population, that is, only patients with previous venous thromboembolism needing standard-intensity warfarin and none with arterial thrombosis related to antiphospholipid syndrome, which is not a licensed indication for direct oral anticoagulants. Because thrombotic antiphospholipid syndrome is clinically heterogeneous, the homogeneity of our study population maximises the clinical applicability of our results. Thrombin generation allows assessment of the anticoagulant effects of warfarin and rivaroxaban despite these drugs' different modes of action. When assessed by endogenous thrombin potential ([ETP] ie, the are under curve) alone, rivaroxaban was inferior to warfarin in terms of anticoagulation intensity, but peak thrombin generation favoured rivaroxaban. Warfarin affects all thrombin generation parameters equally, whereas rivaroxaban mainly affects the initiation and propagation phases of thrombin generation. Formation of the prothrombinase complex is delayed and lag time and time to peak thrombin generation are prolonged and, therefore, the ETP is greater than would be expected for the degree of anticoagulation. Thus, the overall thrombogram indicated no increase in thrombotic risk with rivaroxaban. This conclusion was supported by concentrations of in-vivo coagulation activation markers being increased in only a few patients in both treatment groups,